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SummAry
As l-type voltage-gated calcium channels (VgCCs) control Ca2+ influx and depolarisation of cardiac and vascular smooth muscle, they repre-
sent a specific therapeutic target for calcium channel blockers (CCBs), which are approved and widely used to treat hypertension, myocardial 
ischaemia and arrhythmias. l-type currents also play a role in calcium entry in the sensory cells of the inner ear. in hair cells of both cochlea 
and labyrinth, calcium cytoplasmic influx is the first physiological process that activates complex intracellular enzymatic reactions resulting in 
neurotransmitter release. Excessive calcium ion entry into sensory cells, as a consequence of l-VgCCs malfunction is responsible for over-ac-
tivation of phospholipase A2 and C, protein kinase ii and C, nitric oxide synthase and both endonucleases and depolymerases, which can cause 
membrane damage and cellular death if the cytoplasmic buffering capacity is overcome. nimodipine, a highly lipophilic 1-4 dihydropyridine 
that easily crosses the brain-blood barrier, is generally used to reduce the severity of neurological deficits resulting from vasospasm in patients 
with subarachnoid haemorrhage. moreover, due to its selective blocking activity on l-channel calcium currents, nimodipine is also suggested 
to be an effective countermeasure for cochlear and vestibular dysfunctions known as channelopathies. indeed, experimental data in amphibians 
and mammalians indicate that nimodipine has a stronger efficacy than other CCBs (aminopyridine, nifedipine) on voltage-dependent whole-
cell currents within hair cells at rest and it is the only agent that is also effective during their mechanically induced depolarisation. in humans, 
the efficacy of nimodipine is documented in the medical management of peripheral vestibular vertigo, sensorineural hearing loss and tinnitus, 
even in a pathology as complex as ménière’s disease. nimodipine is also considered useful in the prophylaxis of damage to the facial and 
cochlear nerves caused by ablative surgery of cerebellopontine tumours; it has been recently hypothesised to accelerate functional recovery of 
recurrent nerve lesions during thyroid cancer surgery. Further trials with adequate study design are needed to test the efficacy of nimodipine in 
the treatment of vertigo due to cerebrovascular disease and vestibular migraine.
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riASSunTo
I canali del calcio di tipo L sono indispensabili alla normale contrattilità del miocardio e della muscolatura liscia del sistema vascolare. In 
quanto tali, essi rappresentano uno specifico bersaglio terapeutico di una vasta famiglia di farmaci ad attività calcio-antagonista, che sono 
ampiamente usati per trattare l’ipertensione, l’ischemia miocardica e le aritmie. Tuttavia, i canali del calcio di tipo L svolgono un ruolo deter-
minante anche nel normale funzionamento delle cellule sensoriali nell’orecchio interno. Nelle cellule cigliate, infatti, sia della coclea che del 
labirinto, l’ingresso del calcio all’interno del citoplasma è il primo processo fisiologico che attiva un complesso di meccanismi intracellulari, 
ovvero una sequenza di attivazioni enzimatiche, il cui risultato finale è il rilascio dei neurotrasmettitori a livello delle sinapsi. Al contrario, 
una concentrazione eccessiva di ioni calcio nelle stesse cellule sensoriali, ad esempio come conseguenza di un malfunzionamento dei canali 
del calcio di tipo L, è responsabile dell’attivazione delle fosfolipasi di tipo A2 e C, delle protein-chinasi II e C, dell’ossido nitrico sintetasi che 
possono causare un danno alla membrana plasmatica e la stessa morte cellulare qualora i limiti funzionali dei sistemi tampone del citoplasma 
vengano superati. La nimodipina, un agente altamente lipofilo, appartenente alla famiglia delle 1-4 diidropiridinine, che attraversa facilmente 
la barriera emato-encefalica, è generalmente utilizzata per ridurre la gravità dei deficit neurologici derivanti da vasospasmo nei pazienti con 
emorragia subaracnoidea. Inoltre, a causa della sua azione calcio-antagonista che si esplica selettivamente nei confronti dei canali del calcio 
di tipo L, viene suggerita come trattamento farmacologico efficace principalmente per quelle disfunzioni cocleari e vestibolari che vengono 
considerate delle “canalopatie”. In effetti, i dati sperimentali ottenuti negli anfibi e in alcune specie di mammiferi indicano che nimodipina ha 
maggiore efficacia di altri calcioantagonisti (aminopiridina e nifedipina) nel bloccare le correnti di ioni calcio in ingresso nelle cellule ciliate 
e che è l’unico calcio-antagonista a mantenere tale efficacia anche durante la loro depolarizzazione indotta da stimolo meccanico. Negli esseri 
umani l’efficacia terapeutica della nimodipina è stata documentata nel trattamento della vertigine labirintica, dell’ipoacusia neurosensoriale 
e dell’acufene anche se riferibili ad una patologia complessa e non ancora del tutto chiarita come la malattia di Ménière. La nimodipina è 
inoltre considerata un valido approccio farmacologico nella profilassi dei danni neurali ai nervi facciali e cocleari causati dalla chirurgia 
ablativa dei tumori dell’angolo ponto-cerebellare ed è stata recentemente indicata per accelerare il recupero funzionale delle lesioni del nervo 
ricorrente conseguenti alla chirurgia del cancro alla tiroide. Per verificare, infine, l’efficacia della nimodipina nel trattamento delle vertigini di 
origine centrale, perlopiù associate ai disordini cerebrovascolari, e nel trattamento della vertigine emicranica, sono necessari ulteriori studi 
che confermino con maggiore rigore scientifico tali prospettive, peraltro già ampiamente riportate nella letteratura scientifica.
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Introduction
recent advances in the management of vertigo and tinni-
tus focus on device-related modalities that provide some 
patients with aural symptoms with acceptable results 1, but 
others with less positive ones 2. There is therefore an in-
creasing interest for pharmacological interventions that are 
traditionally used to treat various inner ear diseases and that 
are particularly effective in controlling symptoms if pre-
scribed at higher dosages than in the past 3 and/or as add-on 
medication in multi-component therapy 4. Finally, there is 
accumulating evidence that drugs approved for use in other 
diseases can be prescribed “off-label” to patients affected 
by inner ear dysfunctions with satisfactory results  5. For 
example, the 1-4 dihydropyridine calcium channel blocker 
nimodipine (nmdp) is approved by the Food and drug 
Administration for reducing vasospasm after subarach-
noid haemorrhage and neurological conditions  6. initially 
developed to treat high blood pressure, nmdp was more 
recently suggested to be an effective countermeasure for 
labyrinthine dysfunction 7 8, dizziness due to central nerv-
ous system disorders  9 and migraine-related vertigo  10. it 
has also been shown to prevent reduction of cochlear blood 
flow of different origins  11  12, and represents a potential 
therapeutic option for at least some types of tinnitus 13 14. 
recent experience has shown that nmdp reduces the cal-
cium intracellular overload in traumatised neurons so to ex-
ert an anti-apoptotic effect and improves the rate of nerve 
collateral re-sprouting, axonal growth and re-myelination 
of injured cranial nerves  15  16. Accordingly, its use in the 
prophylaxis and/or reparation of nerve damage occurring 
during head and neck surgery has been proposed 17 18. de-
spite this accumulating experimental and clinical evidence, 
which could potentially expand the prescription of nmdp 
in otolaryngology, its use in clinical practice is far from 
widespread. This manuscript: (a)  briefly summarises the 
nature and function of calcium channels with particular 
attention to their role in auditory and vestibular systems; 
(b) reports on the experimental findings regarding the ap-
plication of nmdp in inner ear function and dysfunction; 
and (c)  reviews the evidence that suggest further indica-
tions for nmdp both as a single strategy or as an adjunct to 
standard care in otolaryngology.
Calcium channels: basic concepts
Voltage-gated calcium channels (VgCCs) are a group of 
ion-conducting pores located in the plasma membrane of 
excitable cells (e.g., muscle, glial cells, neurons, etc.) with 
a selective permeability to the calcium ion (Ca2+). They 
belong to a large family of transmembrane ion channels 
that also include voltage-gated sodium, barium and potas-
sium channels 19. At resting membrane potential, VgCCs 
are normally closed and the concentration of Ca2+ is much 
higher outside of the cell than inside. in response to de-
polarisation, VgCCs allow Ca2+ to enter the cell and pro-
mote exocytosis which, depending on the cell type, results 
in activation of calcium-sensitive potassium channels, 
neurotransmitter and hormone release, muscular contrac-
tion, excitation of neurons and gene expression. The slow 
decline of cytoplasmic Ca2+ concentration after its initial 
rise to a peak level is due to both an increase of ion extru-
sion through a na+Ca2+ exchange system at the plasma 
membrane and to reuptake into internal organelles.
malfunction of VgCCs can lead to an excess of intra-
cellular calcium that over-activates enzymes such as nu-
cleases 20 and phospholipases 21 causing dnA injury and 
breakdown of phospholipids, respectively, which in turn 
irreversibly damage the membrane causing cellular death.
VgCCs are complex proteins composed of distinct subu-
nits (α1, α2δ, β1-4, and γ) (Fig. 1). The α1 subunit with a 
mass of 190 to 250 kda is the largest. it represents the pri-
mary subunit that forms the ion conducting pore necessary 
for channel functioning, determines most of the channel 
voltage-dependent opening and closing behaviours and 
contains the drug/toxin-binding sites. it is encoded by at 
least 10 different genes in mammals. it consists of four 
homologous (i-iV) domains containing six transmem-
brane α-helices each (S1-S6) 22. The other subunits only 
exert an auxiliary modulation of the pharmacological and 
electrophysiological properties of VgCCs 23.
Fig. 1. a) calcium channel structure comprising the α1, α2δ, β, 
and, γ subunits. the α1 subunit, represented here with its 4-fold 
monomeric structure, is responsible for many of the functional 
characteristics of these channels, including the pore voltage-
dependent gating and dihydropyridine binding. the α2 is the 
extracellular glycosylated subunit that interacts with the α1 su-
bunit. the δ subunit has a single transmembrane region with a 
short intracellular portion that serves to anchor the protein in the 
plasma membrane. the β subunit is the only ca2+ channel subu-
nit that is entirely cytoplasmic. the γ1 subunit is a glycoprotein 
that, for the most part, is not required to regulate the channel 
complex. B) the α1 subunit forms the ca2+ selective pore, which 
contains voltage-sensing apparatus and drug/toxin-binding si-
tes. this subunit contains 4 homologous domains (labelled i–iv), 
each containing 6 transmembrane helices (s1–s6).
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multiple types of Ca2+ channels are known and are classi-
fied according to differences in ionic conductance, gating 
modality and pharmacology. For instance, it was initially 
observed that most calcium channels need strong depolar-
isation for opening and are thus are defined “high-voltage 
activated channels”; on the other hand, only a minority 
are activated by weak depolarisation and are referred to 
as “ low-voltage activated channels” 24. A further alpha-
betical nomenclature was proposed for different types of 
calcium currents 25. For instance, most VgCCs are termed 
l-type because they inactivate slowly (“long-lasting”), 
need strong depolarisation to activate and are blocked by 
organic l-type calcium channel antagonists, such as the 
dihydropyridines nifedipine and nmdp 26. They are het-
erotetrameric polypeptide complexes comprising the α1, 
α2δ, β, and, in some tissues, γ subunits. The α1 subunit 
is encoded by CACnA1S, CACnA1C, CACnA1d and 
CACnA1F genes. deficiency in 1d subunit of l-type 
Ca2+ channels causes the absence of l-type Ca2+ currents 
in cochlear inner hair cells and leads to degeneration of 
both outer and inner hair cells, with subsequent congeni-
tal deafness in the mouse 27.
recently, a mutation in CACnA1d, which encodes for 
the pore-forming α1 subunit of Ca(v)1.3 l-type calci-
um channel, has been identified in two consanguineous 
families with deafness. All deaf subjects also showed pro-
nounced sinoatrial node dysfunction at rest  28. Auditory 
sensory hair cells of most species prevalently have l-type 
calcium channels.
p/Q-type calcium channels are present in purkinje neu-
rons in the cerebellum (and thus the name) and in cerebel-
lar granule neurons. They are presynaptic high-voltage-
gated calcium channels that couple neuronal excitation to 
release of neurotransmitter. The α1 subunit is encoded by 
the CACnA1A gene and multiple splice variants exist in 
the central nervous system. malfunction of p/Q channels 
due to mutations are probably associated with familial 
hemiplegic migraine type 1. in the mammalian auditory 
system, p/Q voltage-gated calcium channels modulate 
transmitter release at the olivo-cochlear efferent-inner 
hair cell cholinergic synapses, but their involvement in 
hearing defects is not known.
n-type (‘n’ for “neural-Type”) Ca2+ channels are high-
voltage activated calcium channels present throughout the 
central and peripheral nervous systems at presynaptic ter-
minals. The α1 subunit is encoded by CACnA1B gene. 
n-type voltage-gated calcium channels, as well the p/Q 
type are responsible for the synaptic activation of the in-
hibitory auditory efferent system.
The r-type calcium channel is a unique subtype of VgCC 
as its electrophysiological properties are intermediate be-
tween those of typical high-voltage-activated (p/Q-type, 
n-type, and l-type) or low-voltage-activated (T-type) 
channels. r-type channels are also typically resistant (thus 
the name) to antagonists of l-, n-, and p/Q-type Ca2+ 
channels. They have been identified in various areas of the 
CnS such as the cortex, hippocampus, striatum, amygda-
la, and interpeduncular nucleus and their role is believed 
to be predominantly implicated in spatial memory, fear 
behaviour, pain perception and morphine analgesia. The 
α1 subunit is encoded by CACnA1E gene. Finally, T-type 
calcium channels are distinguished from other VgCCs by 
their low voltage thresholds for activation and inactiva-
tion. “T” stands for transient, referring to the length of 
activation. in many neurons, cytosolic Ca2+ influx through 
lVA channels triggers low-threshold spikes, which in turn 
trigger a burst of action potentials mediated by na+ chan-
nels. T-type calcium channels contribute to the pacemaker 
activity of the sinoatrial node of the heart. The α1 subunit 
is encoded by the CACnA1l gene.
A further classification of calcium channels was proposed 
in 2000 29, based on the chemical symbol of the ion (Ca), 
with the principal physiological regulator (voltage) indi-
cated as a subscript (Cav). The Ca
v
1 subfamily (Cav1.1 
to Cav1.4) includes l-type calcium channels. The Cav2 
(Cav2.1 to Cav2
.
3) includes p/Q-, r-, n-type calcium 
channels and the subfamily Cav3 (Cav3.1 to Cav3.3) 
identifies T-type calcium channels. The aforementioned 
main biochemical properties of VgCCs and their sensi-
tivity to 1,4 dihydropyridine are summarised in Table i.
Calcium channels in the auditory  
and vestibular systems
The free intracellular concentration of calcium (Ca2+) in 
hair cells is very low at rest, but it rapidly increases due 
to entry through clusters of VgCCs in response to acous-
tic stimulation, which primarily allow the entry of cati-
ons close to the stereociglia tips at the cellular apex. The 
Table I. Classification of voltage-gated calcium channels (VGCCs).
Classification of voltage-gated calcium channels (Cav) according to alpha-
betical nomenclature, electrophysiological properties (HVA: high voltage acti-
vated, LVA: low voltage activated), genetic determinants and dihydropyridine 
(DPH) sensitivity.
Type Voltage α1 subunit (gene) 
Chromosome 
DPH 
sensitivity 
L-type calcium 
channel
HVA Cav1.1 (CACNA1S) 1q32 
Cav1.2 (CACNA1C) 12p13.3
Cav1.3 (CACNA1D) 3p14.3  
Cav1.4 (CACNA1F) Xp11.23
Blocked
P/Q-type calcium 
channels
HVA Cav2.1 (CACNA1A) 19p13 Resistant
N-type calcium 
channel 
HVA Cav2.2 (CACNA1B) 9q34 Resistant
R-type calcium 
channel 
Intermediate Cav2.3 (CACNA1E) 1q25.3 Resistant
T-type calcium 
channel 
LVA Cav3.1 (CACNA1G) 17q22 
Cav3.2 (CACNA1H) 
16p13.3 
Cav3.3 (CACNA1L) 22q13.1
Partially 
blocked
D. Monzani et al.
138
calcium release from intracellular stores (endocytosis) is 
actually considered less relevant in this process. Calcium 
promotes vesicles fusion with the presynaptic membrane, 
leading to neurotransmitter release at the baso-lateral cellu-
lar wall 30, in order to activate auditory nerve terminals and 
generate action potential firing patterns. hair cells, as retinal 
bipolar cells and photoceptors, contain ribbon-type active 
zones. The synaptic ribbons are plate-like, proteinaceous 
structures packed with synaptic vesicles. The “ribbon” or 
“dense body” anchors to the presynaptic membrane only 
nanometres away from the clustered VgCCs (Fig. 2). rib-
bons are thought to maintain exocytosis and sustained neu-
rotransmitter release, albeit at reduced rates, in response to 
prolonged sound stimuli 31. The intracellular spread of Ca2+ 
in hair cells is limited by the endogenous buffering activity 
of the cytosol. This system incorporates endogenous fixed 
and mobile Ca2+ buffers that limit the spread of free calcium 
in hair cells and carry incoming Ca2+ away from synaptic 
areas 32. A plasma membrane Ca2+-ATpase type 2 pump is 
responsible for extrusion of calcium from mammalian hair 
cells and its central role in intracellular calcium homeosta-
sis is revealed by the hearing loss resulting from mutations 
in the plasma membrane CaATpase 33. moreover, calcium 
influx into hair cells and its growing concentration opens 
Ca2+-activated k+ channels. The outward k+ flow that fol-
lows repolarises the cell, closing Ca2+ channels and prim-
ing the cell for another cycle of oscillation. The number, 
distribution and kinetics of Ca2+ channels and k+ channels 
determine the characteristic frequency at which a hair cell 
specifically responds and represents the basic process of 
electrical tuning in lower vertebrates’ cochlea 34. The pres-
ence of l-type channels is reported in the olivary nuclei, 
but they express a higher proportion of p/Q-type Ca2+ chan-
nels  35  36 while T-type calcium channels are expressed in 
thalamic projection neurons to cortical auditory areas 37.
The role of VgCCs in the vestibular end-organ is more 
debated. From animal experiments, it appears that the 
majority of VgCCs in semi-circular canals hair cells are 
l-type 38, although an r-type current component has been 
proposed based on its resistance to l- and n-type an-
tagonists 39. Furthermore, an antibody to n-type subunits 
labelled the baso-lateral membranes of type i and type 
ii hair cells 40, but further evidence is needed. Similarly, 
the saccular region displayed at least two different type 
of calcium channels, including l-type, both inhibited by 
nifedipine and promoted by the calcium-channel agonist 
Bay k 8644 41. Besides this uncertainty, the mechanism 
of calcium sequestration for bio-crystallisation from en-
dolymph through calcium pores is partially unknown, so 
that the formation and growth of otoconia remains to be 
elucidated 42. in the brainstem, within the circuitry for the 
vestibulo-ocular reflex (Vor), neurons in the medial ves-
tibular nucleus show adaptive changes in firing rate re-
sponses in relation to Vor gain (the ratio of evoked eye 
velocity to input head velocity). The firing rate response 
of neurons in the medial vestibular nuclei is reduced by 
increasing extracellular calcium and increased either by 
lowering extracellular calcium or with antagonists to 
calcium-dependent potassium channels 43. l-, n- and T-
type calcium channels neurons are present in the medial 
vestibular nuclei  44  45, but their specific contribution to 
vestibular-ocular reflex is not fully understood. The large 
amount of ion-gated channels in hair cells found in these 
experimental studies points to their likely relevant role in 
highly excitable cells of both the cochlea and the laby-
rinth, supporting the hypothesis that inner ear dysfunction 
as complex as ménière’s disease could be interpreted as 
channelopathy, particularly in those cases where familial 
expression of the disease is documented 46.
Nimodipine: from experimental data  
to clinical evidence
nmdp is a calcium channel blocker (CCB) belonging to 
the dihydropyridine class and is a highly lipophilic agent 
that rapidly crosses the blood-brain barrier (Fig.  3). its 
mechanism of action is the selective blockage of intracel-
lular calcium ions influx through l-type VgCCs. nmdp 
exerts a vasoactive effect by predominantly dilating small 
and collateral cerebral vessels, thus improving blood sup-
ply to hypo-perfused (post-ischaemia) areas and cerebral 
oxygenation even in healthy subjects 47. in the inner ear, 
the perilymphatic perfusion of nmdp is known to sup-
press both spontaneous neural noise and compound action 
potential. These are reversible and dose-dependent effects 
and provide support for an exclusively presynaptic role of 
l-type Ca2+ channels in the regulation of both spontane-
ous and evoked neurotransmitter release from hair cells 48. 
Similarly, the guinea pig compound action potential, the 
summating potential and the spontaneous firing of single 
Fig. 2. a) schematic representation of cochlear hair cell structure 
with baso-lateral wall cytoplasmic membrane (marked with cir-
cle) and afferent auditory nerve bottoms; and B) presynaptic “ac-
tive zone” with vesicles and ribbon containing neurotransmitters 
with clustered voltage-gated calcium channel (vGccs).
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cochlear ganglion neurons can be substantially reduced 
by the direct administration of nmdp in the cochlea 49. 
recent findings have shown that deiter’s cells in the 
cochlea not only provide hair cells with supporting activ-
ity, but also contribute to their electrical and biomechani-
cal properties. it has been suggested that these cells mod-
ify cochlear dynamics by influencing the force produced 
by sound-induced motion of outer hair cells, depending 
on their large voltage-activated, outwardly k+ selective 
conductance. Even if voltage-activated Ca2+ currents are 
not present in deiter’s cells, nmdp interacts directly with 
k+ channels in a voltage dependent manner and poten-
tially interferes with depolarisation of the organ of Cor-
ti 50. The role of l-calcium channels in exerting presynap-
tic control on both acoustically provoked and spontaneous 
excitation of auditory nerve fibres appears to be of rele-
vant interest since their abnormal function is suspected to 
be a potential source of annoying symptoms such as tin-
nitus 51. The effect of selective Ca2+ channel agonists and 
antagonists on the afferent neuronal activity of isolated 
frog posterior semicircular canal is clearly document-
ed 52 53; resting activity is substantially affected by all dihy-
dropyridines, whereas only nmdp has been shown to 
significantly reduce the mechanically evoked activity  38. 
in particular, the stronger inhibitory activity of nmdp 
compared with nifedipine, also observed in isolated hair 
cells of the cochlea 54, may be due to their different bio-
physical and conformation-dependent interactions with 
the l-type calcium channel. Their overlapping actions on 
resting discharge could depend on different enzymatic 
patterns involved in rest and mechanically-evoked stimu-
lation 55. Since the underlying pathogenic mechanism of 
ménière’s disease is an over-distension of the membra-
nous structures of both the labyrinth and cochlea (endo-
lymphatic hydrops) that modifies resting discharge of hair 
cells in the absence of sound stimuli and head movements, 
nmdp, cinnarizine and, partially, flunarizine qualify as a 
rational choice for this disease because of their selective 
activity on l-type calcium channels. The effects of me-
chanical over-stimulation of outer hair cells, such as that 
by acoustic trauma, results in excessive entry of Ca2+ in 
hair cells 56 and its sustained intracellular overload primar-
ily activates complex enzymatic reactions, namely phos-
pholipase A2, protein kinase ii and nitric oxide synthase 
that subsequently cause degeneration of the phospholip-
ids of the membrane, cellular lysis and death 57. VgCCs 
are therefore supposed to be involved in the pathogenesis 
of acoustic injury in the auditory system as demonstrated 
by the recording of auditory brainstem responses (ABr) 
and morphological study of the cochlea in ddy mice after 
acoustic over-exposure  58. many experiments in animals 
have been carried out to test the hypothesis that nmdp 
and other l-type calcium channel blockers can protect 
hair cells from acoustic trauma, but the results are so far 
inconclusive  59-61. in guinea pigs, cochlear blood flow 
(CBF) significantly decreases after administration of sa-
licylate (100 mg/kg), but increases after administration of 
nmdp (2 mg/kg). After simultaneous administration of 
both salicylate (100 mg/kg) and nmdp (2 mg/kg), CBF 
remains unchanged. These results suggest that nmdp 
prevents the decrease in CBF induced by salicylate in ani-
mals 62, but no experimental data are available for human 
CBF in relation to administration of VgCCs blockers 
alone or in association with ototoxic drugs. in order to 
study the efficacy of calcium antagonists in vertebrobasi-
lar insufficiency, an animal model of VBi was developed 
by occluding one vertebral artery with a balloon catheter. 
Judging by the reversal of the nystagmic pattern, the 
CCBs flunarizine and nmdp were suggested to be effec-
tive drugs in this animal model 63. The protective effect of 
nmdp with respect to traumatic damage to the auditory 
nerve is documented by a recent study in rats 64. The histo-
logical examination of the temporal bones of nmdp-
treated animals revealed significant preservation of spiral 
ganglion cells in the basal turn of the cochlea in response 
to experimentally provoked compression of the cerebel-
lopontine angle portion of the eighth nerve. in humans, a 
prospective, randomised, double-blind study to assess the 
intra-operative efficacy of diltiazem (a non-dihydropyri-
dine member of the calcium channel blocker family com-
monly used to treat hypertension and angina pectoris) in 
preventing acoustic trauma during otologic surgery was 
carried out in 1995 65. The results were influenced by a 
small postoperative sensorineural hearing loss in all cases 
(treated and placebo) and by the tendency for better pres-
ervation of the bone-conduction hearing threshold in the 
therapy group, although this did not reach statistical sig-
nificance. no further trials regarding this possible indica-
tion have been reported to date. on the other hand, pro-
phylactic treatment with nmdp is definitively shown to 
be effective in reducing both facial and cochlear nerve 
damage in humans due to vestibular schwannoma sur-
gery 17 66-68 by improving axon regeneration and collateral 
sprouting. one study 17 showed that all patients who had 
received nmdp and hydroxyethyl starch-based prophy-
Fig. 3. chemical structure and formula of nimodipine. 3-(2-me-
thoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate c21H26n2o7.
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laxis had a significant recovery of facial nerve function 
(house-Brackmann grade i-ii) compared with preopera-
tive staging (house-Brackmann grade iii or worse), 
whereas one third of patients with pre-operative facial 
nerve paresis (house-Brackmann grade iii or worse) who 
had not received such prophylactic treatment were un-
changed at long-term follow-up post-operation. in addi-
tion, in more than 50% of patients undergoing surgical 
removal of vestibular schwannoma without prophylactic 
medication, intraoperative brainstem auditory evoked po-
tentials monitoring showed a sudden or slowly progres-
sive loss of potentials. despite prompt initiation of intra-
operative vasoactive treatment, preservation of hearing 
function could not be obtained, suggesting that prophy-
laxis is superior to intraoperative vasoactive treatment. in 
a recent experience, the resected recurrent nerve due to 
removal of a thyroid cancer was repaired with a nerve 
graft and the patient was further treated with nimodipine 
for 3 months. After therapy, the electromyography showed 
complete re-innervation of laryngeal muscles 18. This ex-
perience suggests the potential utility of nmdp as add-on 
therapy to prevent and/or facilitate re-innervation of both 
superior and recurrent laryngeal nerve lesions that may 
occur during thyroid surgery 69 70 or of other nerves that 
could be damaged during neck dissection 71. The use of 
CCBs in the treatment of peripheral vertigo has been re-
ported for many years in Europe 72 and their efficacy and 
safety has been tested in two double-blind studies that in-
cluded different types of peripheral vestibular vertigo 8 73. 
in the first study, the effectiveness of nmdp (30 mg three 
times daily) was compared to cinnarizine (150  mg per 
day); after 12 weeks of treatment, the former drug reduced 
the incidence of moderate vertigo attacks to 78.8% of 
cases, and of severe vertigo in 85% of cases, whereas cin-
narizine reduced 65.8% of moderate vertigo episodes and 
89.8% of severe ones. Both nmdp and cinnarizine exhib-
ited a significant therapeutic effect and similar safety pro-
file. in the second study, conventional nmdp was admin-
istrated three times daily at a dosage of 30  mg in 26 
patients and its effect compared to that of an extended 
release formulation (90 mg, once a day) in 25 patients. 
After 8 weeks of extended release drug treatment, about 
90% of both vertigo disability and severity was rated as 
decreased by 50%. in the conventional group, rating of 
severity was reduced by 50% in 90% of patients after 8 
weeks whereas vertigo disability was decreased by 50% 
in 64% of cases. no significant difference was found be-
tween groups and both drug regimens were considered ef-
fective and well tolerated. while the aforementioned stud-
ies investigated the effectiveness of nmpd in the 
treatment of miscellaneous peripheral vestibular disor-
ders, only one pilot study specifically explored the benefi-
cial use of nmdp as monotherapy in medical treatment 
of ménière’s disease  7. nmdp was prescribed to mé-
nière’s disease patients whose first-line medical treatment 
(diuretics, salt dietary restriction and vestibular suppres-
sants) was not effective in controlling vertigo, or amelio-
rating or stabilising hearing loss. A recent retrospective 
analysis 14 of 10-year experience in the long-term manage-
ment of patients affected by definite ménière’s disease, 
diagnosed according to the American Academy of otolar-
yngology-head and neck Surgery Committee on hearing 
and Equilibrium diagnostic guidelines, highlighted a spe-
cific effect of nmdp as an add-on therapy for cochlear 
dysfunction 74. This study documented that a fixed combi-
nation of nmdp (at a dose of 40 mg a day) and betahis-
tine (at a dose of 32 mg a day) for six months was more 
effective than monotherapy with betahistine (at a dose of 
32 mg a day) for the same period in reducing the number 
of vertigo attacks, subjective annoyance due to tinnitus 
and severity of sensorineural hearing loss. These data sug-
gest that nmdp should be prescribed as an add-on thera-
py in the long-term medical management of ménière’s 
disease in consideration of its efficacy on cochlear symp-
toms. This result confirms previous evidence on the ben-
eficial effect of nmdp on tinnitus in both humans 13 and 
animal models 75. drug treatments are not commonly used 
for benign paroxysmal positional vertigo because differ-
ent repositioning manoeuvres are now available to cure 
the unusual manifestations of otolith dysfunction 76 77, but 
it could be speculated that CCBs offer an attempt to pre-
vent flare-ups in patients who are also affected with other 
peripheral vestibulopathies 78.
Finally, in order to test the effect of nmdp on the 
haemorheology and brainstem auditory evoked poten-
tials (BAEp) in patients with vertebrobasilar insufficiency 
(VBi), a pilot study on 50 cases was carried out 79. patients 
were divided into a nmdp group (25 cases) and a thera-
py-as-usual group (25 cases). Compared with the therapy-
as-usual group, plasma viscosity was markedly decreased 
(p  <  0.05) in the nmdp group, and peak latency of V 
wave, inter-peak latency of iii-V and i-V were also im-
proved significantly (p < 0.05). it was therefore suggested 
that nmpn could ameliorate central auditory pathway 
function through its beneficial effect on haemorheology in 
patients with vertebrobasilar insufficiency. This study fur-
ther confirms  the possible role of nimodipine in vestibu-
lar disorders since it has been shown that vertigo may also 
arise from cerebellar and cerebral vascular diseases 80, as 
reported below.
Further strategies and applications
Nimodipine and vertigo/dizziness of vascular origin
Vestibular compensation is a progressive neural process 
taking place in the central nervous system, which recali-
brates vestibulo-oculomotor and vestibulo-spinal reflex-
es after peripheral vestibular-end organ failure and/or a 
vestibular (Viii nerve) neuritis. its evolution is generally 
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thought to be complete and recovery may be achieved 
in a relatively short time in most cases. however, some 
patients complain of residual symptoms such as postural 
instability and episodic vertigo for long periods of time.
A single cause for this delayed compensation process is 
seldom identifiable and a multifactorial pathogenesis is 
most likely. For example, persistent vertigo and dizziness 
are more frequently observed in patients with cerebro-
vascular disease affecting those specific central nervous 
system areas and neural pathways that are supposed to be 
directly involved in vestibular compensation 81. moreover, 
it has been largely confirmed that patients with balance 
and gait disorders have a higher incidence of mri white 
matter hyper-intensities due to white matter ischaemic 
disease and hypertension, so that cerebrovascular disor-
ders may account for persistent vertigo per se 82. Since the 
beneficial effects of nmdp on age-related cerebrovascu-
lar disorders in animals 83 and in human clinical trials 84-86 
are extensively documented, its use has been proposed in 
the treatment of vertigo in such patients. interestingly, a 
study on elderly patients with chronic brain failure who 
received a single 30 mg oral dose of nmdp followed by 
two weeks treatment at a dose of 30 mg three times a day 
showed a significant amelioration of dizziness 87.
it should be added that both cerebrovascular diseases  88 
and vertigo 89 are often associated with depression, a rel-
evant cause of significant comorbidity. in a double-blind, 
randomised clinical trial 90, 101 patients diagnosed with 
“vascular depression” treated with fluoxetine at standard 
doses were randomised to placebo or nmdp administra-
tion. Treatment outcomes were assessed by the hamil-
ton depression rating Scale. depression was decreased 
in both groups, but a greater improvement and a lower 
percentage of recurrence were seen in fluoxetine-nmdp 
patients. it should be added that in a previous multicen-
tre, placebo-controlled, double-blind clinical study in 178 
elderly patients with cognitive decline  91, nmdp alone 
seemed to exert an antidepressant effect. unfortunately, 
the exact mechanism of the probable antidepressant ac-
tion of nmdp is unclear.
Finally, unlike other calcium channel blockers, nmdp 
can also modulate other calcium-dependent processes 
such as acetylcholine release, which is potentially of ben-
efit in improving vestibular compensation in the elderly 
affected by uncompensated peripheral vestibular disor-
ders and mild cognitive impairment due to cerebrovascu-
lar diseases 92.
All these results clearly suggest a potential effect of 
nmpd in the pharmacological treatment of patients with 
uncompensated peripheral associated with cerebral vas-
cular diseases presenting with persistent and recurrent 
dizziness. This indication seems to be most relevant in 
dizzy patients, and the elderly in particular, who are also 
affected by mood disturbance. Further investigations with 
appropriate study-designs are needed.
Nimodipine and vestibular migraine
Vestibular migraine (Vm), also known as migraine-as-
sociated vertigo, is a common cause of dizziness in the 
adult population 93 94, but in a large percentage of patients 
with vertigo, Vm is under-diagnosed. Symptoms include 
spontaneous and positional vertigo, light-headedness and 
unsteadiness of variable duration, ranging from seconds 
to days. Some patients report a temporal relationship with 
the headache episode, but most do not. The wide vari-
ability in clinical presentation of patients with Vm, lack 
of a generally accepted pathophysiologic model linking 
migraine and vertigo and the absence of specific biomark-
ers for the disease underlie the lack of commonly used 
criteria for diagnosis 95. A recent classification of vestibu-
lar migraine 96 postulates that a diagnosis of Vm must be 
formulated on the basis of the following criteria:
•	 at least 5 episodes with vestibular symptoms of moder-
ate or severe intensity, lasting 5 min to 72 hours;
•	 current or previous history of migraine with or with-
out aura according to the international Classification of 
headache disorders (iChd);
•	 one or more migraine features with at least 50% of ves-
tibular episodes:
– headache with at least two of the following charac-
teristics:
• one sided location, pulsating quality, moderate 
or severe pain intensity, aggravation by routine 
physical activity;
• photophobia and phonophobia;
• visual aura;
•	 not better accounted for by another vestibular or iChd 
diagnosis.
unfortunately, no standard medical treatment for acute 
attacks of Vm is available, whereas prophylactic medica-
tions have been proposed.
A review of the pharmacological treatments of Vm 
showed that common drugs routinely used in migraine 
prophylaxis (triptans, CCBs, nortriptyline, or metopro-
lol) can also be successfully prescribed to patients with 
Vm 97. This finding has been recently confirmed by a ret-
rospective analysis of ‘epigone’ migraine vertigo, a type 
of vertigo, migrainous in origin, starting late in lifetime 
and replacing, as an equivalent, a pre-existing migraine 
headache 98. This study reported successful results in the 
prophylaxis of both headache and vertigo spells after the 
administration of flunarizine. in addition, emerging clini-
cal evidence supports not only a strong association be-
tween migraine and ménière’s disease 99, but also clearly 
indicates that patients with episodic vertigo, fluctuating 
hearing loss and migraine respond better to CCBs than to 
anti-hydropic drugs 100 101.
The efficacy of nmdp in prophylaxis of migraine has 
been extensively investigated, but the results of placebo-
controlled trials are controversial. Three of six compara-
tive trials with placebo suggested no significant differ-
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ence 102-104, while the remaining three reported relatively 
large and statistically significant treatment effects  105-107. 
This discrepancy could be due to many factors such as dif-
ferent types of migraine/headache included in the studies, 
dosages and duration of treatments and outcome meas-
ures used.
Taken together, these observations suggest an expanding 
indication for the use of nmdp in Vm, but its potential 
efficacy needs to be documented in clinical trials with ad-
equate study design.
Conclusions
The l-type calcium channel blocker nmdp has been 
widely utilised in numerous experimental and clinical 
investigations, far beyond its internationally approved 
indication. primarily due to its vasoactive and neuropro-
tective effects on both the inner ear and the brain, it may 
be beneficial in many otoneurological syndromes, both 
peripheral, central and mixed, as monotherapy or as an 
add-on therapy to standard regimens. its greater efficacy 
on aural symptoms such as tinnitus and hearing loss, if 
prescribed in association to betahistine compared to beta-
histine alone in the treatment of ménière’s disease, should 
be considered by otolaryngologists and audiologists and 
included in their routine pool of possible medications.
Since cerebrovascular lesions often cause gait distur-
bances and dizziness, and represent a possible cause of un 
uncompleted compensation of vestibular end-organ dis-
eases, nmdp, by facilitating perfusion and oxygenation 
of human brain hypoxic areas, appears to be a rational 
choice in the treatment of vertigo of vascular origin. de-
spite existing uncertainties about the origin of vestibular 
migraine, it has been recently confirmed that patients suf-
fering from this disease can be successfully treated with 
anti-migraine drugs so that nmdp may be an effective 
medical option considering both its efficacy as a migraine 
prophylactic drug and activity in inner ear disorders.
A more restricted field of application for nmdp is the 
surgery of the eighth nerve and cerebello-pontine angle 
lesions because of its neuroprotective effects, which are 
useful in preventing damage to both facial and cochlear 
nerves. it should be finally noted that despite increasing 
indications for the use of nmdp in otolaryngology, its 
prescription is still off-label in this field and informed 
consent should be obtained by patients before use.
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